EGFR and non-small cell lung carcinoma: ICI monotherapy exhibited the lowest toxicity profile.<h4>Conclusions</h4>These findings indicate that ICI+antiangiogenesis+chemo may be potentially beneficial for patients with EGFR-mutated NSCLC.